Precision bioconjugation and intracellular trafficking assays to uncover therapeutic antibody performance

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Precision bioconjugation and intracellular trafficking assays to uncover therapeutic antibody performance

A major bottleneck for the ADCs field is the ability to confidently determine whether an antibody not only binds its target, but is internalized, trafficked to lysosomes, and processed in a way that enables effective payload release. Traditional approaches often require indirect measurements, multi-step validation, or low-throughput workflows that slow candidate selection and ultimately increase late-phase development risk.

This webinar will equip attendees with practical strategies to overcome key challenges in antibody and ADC development. A detailed technical presentation with integrated data walkthroughs will also feature short case highlights demonstrating how site-specific labeling improves sensitivity and reproducibility over traditional random labeling. Examples using both currently approved biotherapeutics and potential early discovery candidates will be shared to demonstrate robust, site-specific fluorescent readouts of lysosomal delivery that correlate with functional ADC performance.

Attend this webinar to gain actionable insights that will help you to:

Reduce uncertainty in early candidate screening by linking internalization and lysosomal processing to downstream functional outcomes
Improve efficiency through rapid, site-specific labeling workflows that preserve antibody function while minimizing variability
Differentiate between surface binding, internalization, and true lysosomal degradation—critical for predicting ADC efficacy
Generate reproducible, quantitative data suitable for high-content imaging and flow cytometry platforms
Stay ahead of emerging trends in biotherapeutic characterization

Chris Langsdorf

Product Manager at Thermo Fisher Scientific

Chris is a Global Product Manager leading cross-functional teams developing advanced sensor and labeling technologies for fluorescence-based detection and single-cell analysis. With over 18 years of experience, he has driven the development of more than 200 innovative reagents supporting flow cytometry, fluorescence microscopy, and therapeutic research, including antibodies, ADCs, and cell therapies. He manages a global portfolio focused on bioconjugation and fluorescence, shaping product strategy, lifecycle management, and market expansion initiatives.

Having delivered nearly 700 seminars across 40+ countries, Chris has built a strong international network of key opinion leaders that informs product innovation and accelerates adoption. His strategic collaborations integrate reagents, assays, and instrumentation to advance comprehensive cell analysis solutions at Thermo Fisher Scientific.

In 32 Days

You have registered for this webinar